Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Detectnet (copper Cu 64 dotatate injection) is indicated for use with positron emission tomography (PET) for localization of somatostatin receptor-positive neuroendocrine tumors (NETs) in adults.
• This summary is based on the review of two randomized controlled trial(s). ^[1-2]
• In patients with type 2 diabetes, liraglutide treatment for 26 weeks significantly reduced [⁶⁴Cu]Cu-DOTATATE uptake values in coronary inflammation, with participant-level SUV_max (p=0.013) and mSUV_max (p=0.004) showing significant reductions. At the coronary-segment level, SUV_max (p=0.001) and mSUV_max (p<0.0001) also showed significant decreases. The placebo group showed no significant change in uptake values.
• In patients with somatostatin receptor (SSTR)-expressing neuroendocrine tumors (NETs), [⁶⁴Cu]Cu-DOTATATE PET/CT demonstrated high diagnostic performance, with a sensitivity of 90.9% (p=0.0042) and specificity of 96.6% (p<0.0001). After correcting an initial misread, sensitivity increased to 100.0% and specificity to 96.8%, indicating effective detection of localized and metastatic disease.
• The first study on coronary inflammation and atherosclerosis did not report specific safety outcomes or adverse effects related to the use of [⁶⁴Cu]Cu-DOTATATE.
• In the second study on neuroendocrine tumors (NETs), no adverse events related to [⁶⁴Cu]Cu-DOTATATE were observed, and there were no serious adverse events reported, indicating a favorable safety profile for this radiopharmaceutical.
• There is no population types or subgroups information available in the reviewed studies.